User menu

Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations

Bibliographic reference Douxfils, Jonathan ; Mani, Helen ; Minet, Valentine ; Devalet, Bérangère ; Chatelain, Bernard ; et. al. Non-VKA oral anticoagulants: Accurate measurement of plasma drug concentrations. In: BioMed Research International, Vol. 2015, p. 345138 [1-13] (2015)
Permanent URL
  1. Bloemen Saartje, De Laat Marieke, De Laat Bas, Hemker Hendrik Coenraad, Al Dieri Raed, Will One Size of Anticoagulant Dosage Fit All? : Commentary, 10.1002/ddr.21097
  2. ten Cate Hugo, New oral anticoagulants: discussion on monitoring and adherence should start now!, 10.1186/1477-9560-11-8
  3. Nutescu Edith, Chuatrisorn Ittiporn, Hellenbart Erika, Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, 10.1007/s11239-011-0561-1
  4. CPT: Pharmacometrics & Systems Pharmacology, 3, e136 (2014)
  5. LIESENFELD K.-H., LEHR T., DANSIRIKUL C., REILLY P. A., CONNOLLY S. J., EZEKOWITZ M. D., YUSUF S., WALLENTIN L., HAERTTER S., STAAB A., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial : Population pharmacokinetics of dabigatran>, 10.1111/j.1538-7836.2011.04498.x
  6. Mueck Wolfgang, Stampfuss Jan, Kubitza Dagmar, Becka Michael, Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, 10.1007/s40262-013-0100-7
  7. MISMETTI P., LAPORTE S., New oral antithrombotics: a need for laboratory monitoring. For, 10.1111/j.1538-7836.2010.03764.x
  8. ten Cate H., Monitoring new oral anticoagulants, managing thrombosis, or both? : , 10.1160/th12-03-0130
  9. Pare G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M. D., Axelsson T., Haertter S., Oldgren J., Reilly P., Siegbahn A., Syvanen A.-C., Wadelius C., Wadelius M., Zimdahl-Gelling H., Yusuf S., Wallentin L., Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding, 10.1161/circulationaha.112.001233
  10. Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
  11. Ehrenschwender M., Koessler J., Brunner K., Steigerwald U., A 77-Year-Old Man with a Prolonged Activated Partial Thromboplastin Time, 10.1373/clinchem.2011.168393
  12. Legrand Matthieu, The Use of Dabigatran in Elderly Patients, 10.1001/archinternmed.2011.314
  13. Lillo-Le Louët A., Wolf M., Soufir L., Galbois A., Dumenil A.-S., Offenstadt G., Samama M.-M., Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation : , 10.1160/th12-03-0149
  14. The American Journal of Emergency Medicine, 31, 443.e1 (2013)
  15. Yokoi Kensuke, Isoda Kikuo, Kimura Toyokazu, Adachi Takeshi, Diffuse Alveolar Hemorrhage Associated with Dabigatran, 10.2169/internalmedicine.51.8345
  16. BOUNAMEAUX H., REBER G., New oral antithrombotics: a need for laboratory monitoring. Against, 10.1111/j.1538-7836.2010.03759.x
  17. PENGO V., CRIPPA L., FALANGA A., FINAZZI G., MARONGIU F., MOIA M., PALARETI G., POLI D., TESTA S., TIRAFERRI E., TOSETTO A., TRIPODI A., SIRAGUSA S., MANOTTI C., Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results : Novel anticoagulants in atrial fibrillation, 10.1111/j.1538-7836.2012.04866.x
  18. Drug Design, Development and Therapy, 8, 789 (2014)
  19. Turpie A. G. G., Kreutz R., Llau J., Norrving B., Haas S., Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor : , 10.1160/th12-03-0209
  20. Huber K., Airaksinen K. J., Cuisset T., Marín F., Rubboli A., Lip G. Y. H., Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe : , 10.1160/th11-08-0602
  21. Faxon D. P., Eikelboom J. W., Berger P. B., Holmes D. R., Bhatt D. L., Moliterno D. J., Becker R. C., Angiolillo D. J., Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting : A North-American perspective, 10.1160/th11-04-0262
  22. Sample integrity and preanalytical variables, 45 (2013)
  23. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  24. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.-M., Impact of dabigatran on a large panel of routine or specific coagulation assays : Laboratory recommendations for monitoring of dabigatran etexilate, 10.1160/th11-11-0804
  25. Van Blerk M., Bailleul E., Chatelain B., Demulder A., Devreese K., Douxfils J., Jochmans K., Mullier F., Wijns W., Soumali M. R., Coucke W., Vernelen K., Van de Walle P., Influence of dabigatran and rivaroxaban on routine coagulation assays : A nationwide Belgian survey, 10.1160/th14-02-0161
  26. Antovic Jovan P., Skeppholm Mika, Eintrei Jaak, Boija Elisabet Eriksson, Söderblom Lisbeth, Norberg Eva-Marie, Onelöv Liselotte, Rönquist-Nii Yuko, Pohanka Anton, Beck Olof, Hjemdahl Paul, Malmström Rickard E., Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma, 10.1007/s00228-013-1550-4
  27. Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
  28. Hawes E. M., Deal A. M., Funk-Adcock D., Gosselin R., Jeanneret C., Cook A. M., Taylor J. M., Whinna H. C., Winkler A. M., Moll S., Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels, 10.1111/jth.12308
  29. Hapgood G., Butler J., Malan E., Chunilal S., Tran H., The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples : , 10.1160/th13-04-0301
  30. Lippi Giuseppe, Salvagno Gian Luca, Ippolito Luigi, Franchini Massimo, Favaloro Emmanuel J, Shortened activated partial thromboplastin time: causes and management : , 10.1097/mbc.0b013e328338dbe8
  31. KITCHENS C. S., To bleed or not to bleed? is that the question for the PTT?, 10.1111/j.1538-7836.2005.01552.x
  32. Eikelboom John W., Hirsh Jack, Monitoring unfractionated heparin with the aPTT: Time for a fresh look, 10.1160/th06-05-0290
  33. Hirsh Jack, Warkentin Theodore E., Shaughnessy Stephen G., Anand Sonia S., Halperin Jonathan L., Raschke Robert, Granger Christopher, Ohman E. Magnus, Dalen James E., Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety, 10.1378/chest.119.1_suppl.64s
  34. Mueck Wolfgang, Eriksson Bengt I, Bauer Kenneth A, Borris Lars, Dahl Ola E, Fisher William D, Gent Michael, Haas Sylvia, Huisman Menno V, Kakkar Ajay K, Kälebo Peter, Kwong Louis M, Misselwitz Frank, Turpie Alexander G G, Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery : , 10.2165/00003088-200847030-00006
  35. TRIPODI A., CHANTARANGKUL V., GUINET C., SAMAMA M. M., The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study : Letters to the Editor, 10.1111/j.1538-7836.2010.04106.x
  36. Baglin T., The role of the laboratory in treatment with new oral anticoagulants, 10.1111/jth.12227
  37. Barrett Y. C., Wang Z., Frost C., Shenker A., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay : , 10.1160/th10-05-0328
  38. Samama M. M., Martinoli J.-L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., Perzborn E., Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor : , 10.1160/th09-03-0176
  39. HILLARP A., BAGHAEI F., FAGERBERG BLIXTER I., GUSTAFSSON K. M., STIGENDAL L., STEN-LINDER M., STRANDBERG K., LINDAHL T. L., Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays : Effects of rivaroxaban on coagulation assays, 10.1111/j.1538-7836.2010.04098.x
  40. Douxfils Jonathan, Mullier François, Loosen Claire, Chatelain Christian, Chatelain Bernard, Dogné Jean-Michel, Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature, 10.1016/j.thromres.2012.09.004
  41. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.-M., Mullier F., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban : , 10.1160/th13-04-0274
  42. van Veen Joost J., Smith Julie, Kitchen Steve, Makris Mike, Normal prothrombin time in the presence of therapeutic levels of rivaroxaban, 10.1111/bjh.12173
  43. Rodgers Ryan, Bagot Catherine N., Lawrence Caroline, Hickman Grainne, McGurk Michael, Tait Robert Campbell, Correlating prothrombin time with plasma rivaroxaban level, 10.1111/bjh.12566
  44. Harenberg J., Du S., Weiss C., Krämer R., Hoppensteadt D., Walenga J., , Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH, 10.1111/jth.12547
  45. Becker R. C., Alexander J. H., Newby L. K., Yang H., Barrett Y., Mohan P., Wang J., Harrington R. A., Wallentin L. C., Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome : , 10.1160/th10-04-0247
  46. Douxfils J., Chatelain C., Chatelain B., Dogné J.-M., Mullier F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide : , 10.1160/th12-12-0898
  47. Frost Charles, Nepal Sunil, Wang Jessie, Schuster Alan, Byon Wonkyung, Boyd Rebecca A., Yu Zhigang, Shenker Andrew, Barrett Yu Chen, Mosqueda-Garcia Rogelio, LaCreta Frank, Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects : Apixaban multiple dose safety, PK and PD, 10.1111/bcp.12106
  48. Gouin-Thibault I., Flaujac C., Delavenne X., Quenet S., Horellou M.-H., Laporte S., Siguret V., Lecompte T., Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays : A multicentre French GEHT study, 10.1160/th13-06-0470
  49. Moore Gary, Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants, 10.1055/s-0033-1364185
  50. VAN OS G. M. A., DE LAAT B., KAMPHUISEN P. W., MEIJERS J. C. M., DE GROOT PH. G., Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time : Letters to the Editor, 10.1111/j.1538-7836.2011.04395.x
  51. Merriman E., Kaplan Z., Butler J., Malan E., Gan E., Tran H., Rivaroxaban and false positive lupus anticoagulant testing : , 10.1160/th10-08-0511
  52. Exner T., Ellwood L., Rubie J., Barancewicz A., Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study : , 10.1160/th12-11-0842
  53. Altman Raul, Gonzalez Claudio, Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs, 10.1186/1477-9560-12-7
  54. van Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M., Clemens A., Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity : , 10.1160/th09-11-0758
  55. Stangier Joachim, Feuring Martin, Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran : , 10.1097/mbc.0b013e32834f1b0c
  56. Gosselin Robert C., Dwyre Denis M., Dager William E., Measuring Dabigatran Concentrations Using a Chromogenic Ecarin Clotting Time Assay, 10.1177/1060028013509074
  57. Nowak Götz, The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin Inhibitors, 10.1159/000081505
  58. Lange U., Nowak G., Bucha E., Ecarin Chromogenic Assay – A New Method for Quantitative Determination of Direct Thrombin Inhibitors Like Hirudin, 10.1159/000081506
  59. Douxfils Jonathan, Tamigniau Anne, Chatelain Bernard, Goffinet Catherine, Dogné Jean-Michel, Mullier François, Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays, 10.1186/1477-9560-12-24
  60. Kubitza Dagmar, Becka Michael, Wensing Georg, Voith Barbara, Zuehlsdorf Michael, Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects, 10.1007/s00228-005-0043-5
  61. Samama M. M., Amiral J., Guinet C., Perzborn E., Depasse F., An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma : , 10.1160/th10-03-0204
  62. Asmis L.M., Alberio L., Angelillo-Scherrer A., Korte W., Mendez A., Reber G., Seifert B., Stricker H., Tsakiris D.A., Wuillemin W.A., Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests, 10.1016/j.thromres.2011.06.031
  63. GEROTZIAFAS G. T., ELALAMY I., DEPASSE F., PERZBORN E., SAMAMA M. M., In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban, 10.1111/j.1538-7836.2007.02429.x
  64. Harenberg Job, Krämer Roland, Giese Christina, Marx Svetlana, Weiss Christel, Wehling Martin, Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability, 10.1007/s11239-011-0622-5
  65. Mani H., Hesse C., Stratmann G., Lindhoff-Last E., Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time : , 10.1160/th10-10-0667
  66. Mani H., Rohde G., Stratmann G., Hesse C., Herth N., Schwers S., Perzborn E., Lindhoff-Last E., Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin : , 10.1160/th11-12-0832
  67. Samama M. M., Contant G., Spiro T. E., Perzborn E., Guinet C., Gourmelin Y., Le Flem L., Rohde G., Martinoli J. L., , Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls : , 10.1160/th11-06-0391
  68. Francart S. J., Hawes E. M., Deal A. M., Adcock D. M., Gosselin R., Jeanneret C., Friedman K. D., Moll S., Performance of coagulation tests in patients on therapeutic doses of rivaroxaban : A cross-sectional pharmacodynamic study based on peak and trough plasma levels, 10.1160/th13-10-0871
  69. Becker Richard C., Yang Hongqiu, Barrett Yuchen, Mohan Puneet, Wang Jessie, Wallentin Lars, Alexander John H., Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor, 10.1007/s11239-011-0591-8
  70. Du Shanshan, Krämer Sandra, Giese Christina, Schulze Astrid, Weiss Christel, Krämer Roland, Harenberg Job, Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples, 10.1055/s-0032-1331155
  71. Harenberg Job, Krämer Sandra, Du Shanshan, Weiss Christel, Krämer Roland, Concept of a point of care test to detect new oral anticoagulants in urine samples, 10.1186/1477-9560-11-15
  72. Harenberg Job, Krämer Sandra, Du Shanshan, Zolfaghari Shabnam, Schulze Astrid, Krämer Roland, Weiss Christel, Wehling Martin, Lip Gregory Y. H., Measurement of rivaroxaban and apixaban in serum samples of patients, 10.1111/eci.12291
  73. Pernod Gilles, Albaladejo Pierre, Godier Anne, Samama Charles M., Susen Sophie, Gruel Yves, Blais Normand, Fontana Pierre, Cohen Ariel, Llau Juan V., Rosencher Nadia, Schved Jean-François, de Maistre Emmanuel, Samama Meyer M., Mismetti Patrick, Sié Pierre, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, 10.1016/j.acvd.2013.04.009